NCT07005752 - A Study to Evaluate the Efficacy and Safety of CnU Capsule 750 mg in Patients With Cholesterol Gallstones(GB Stones). | Biotech Hunter

Enrollment

484

Participants

Timeline

Start Date

July 28, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions

Cholesterol Cholelithiasis

Interventions

DRUG

CnU cap. 250mg & Ursa placebo tab. 200mg

CnU capsule(Magnesium Salt Trihydrate of Chenodeoxycholic Acid and Ursodeoxycholic Acid) and Ursa placebo tablet will be orally administered three times a day after meals at regular intervals for a total of 24 weeks.

DRUG

Ursa tab. 200mg & CnU placebo cap. 250mg

Ursa tablet(Ursodeoxycholic Acid) and CnU placebo capsule will be orally administered three times a day after meals at regular intervals for a total of 24 weeks.

Trial Locations (6)

Unknown

RECRUITING

Pusan National University Hospital, Busan

RECRUITING

CHA Bundang Medical Center, Gyeonggi-do

RECRUITING

Hallym University Dongtan Sacred Heart Hospital, Gyeonggi-do

RECRUITING

Soonchunhyang University Cheonan Hospital, Gyeonggi-do

RECRUITING

Inha University Hospital, Incheon

RECRUITING

Gangnam Severance Hospital, Seoul

All Listed Sponsors

lead

Myungmoon Pharma. Co. Ltd.

INDUSTRY